Trials / Not Yet Recruiting
Not Yet RecruitingNCT07408869
A Phase 1 Study of Cizutamig in IgE Mediated Diseases
A Phase 1b, Open-Label Study Evaluating the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Cizutamig in IgE Mediated Diseases
- Status
- Not Yet Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Candid Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Detailed description
This is a Phase 1b, open-label study evaluating the pharmacodynamics, safety, tolerability, pharmacokinetics, and immunogenicity of cizutamig in IgE Mediated Diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Cizutamig | cizutamig will be dosed SC according to the assigned cohort |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2026-12-01
- Completion
- 2026-12-01
- First posted
- 2026-02-13
- Last updated
- 2026-04-16
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT07408869. Inclusion in this directory is not an endorsement.